NOVARTIS, INC.

TRD · Trade (domestic/foreign)

Outbound investment issues.

HCR · Health Issues

Direct to Consumer Advertising. 340B Drug Discount Program - Program Implementation & Oversight. Accelerated Approval. Breast Cancer Research. Supply Chain Integrity and Traceability. PBM Reform. Coverage of Accelerated Approval Products. Drug Benefit Design. Orphan Drug Issues. S. 1682/H.R.946: ORPHAN Cures Act. Reimbursement and Coverage of Innovative Products. Lower Costs, More Transparency Act. Lower Costs, More Cures Act. Patient Cost-Sharing. Step Therapy. Value-based Contracting and Communications. User fee policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Drug importation policy issues. Competition policy issues. Drug shortages policy issues. IRA price negotiation expansion policy issues. Rare Pediatric Disease Priority Review Voucher program policies. SUSTAIN RFI/discussion draft. Most Favored Nation (MFN) policy. Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Utilization management policies.

Literal federal measure citations: S. 1682, H.R.946

MMM · Medicare/Medicaid

Medicare Part B. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues. H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025. Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. Medicaid rebate policy issues.

Literal federal measure citations: H.R.1672